CJC-1295 and Ipamorelin: Strong Components, Absent Combination Data

The short version

CJC-1295 / ipamorelin is not one compound. It is two peptides used together: CJC-1295, a modified copy of the body's own growth-hormone-releasing hormone, and ipamorelin, which acts on a different receptor on the same pituitary cells. The idea is that pressing two separate buttons at once produces a larger release of growth hormone than pressing either alone.

The idea has decent laboratory support and no clinical proof. There is no published human trial of the pair. Everything said about the combination is assembled from studies of each half separately, plus general work on how the two receptor pathways interact inside cells.

A further complication rarely mentioned: the two halves run on very different clocks. The long-acting form of CJC-1295 stays bound to a blood protein for days, while ipamorelin is cleared in hours. This page reports what each half's own studies measured, and marks clearly where the evidence for the combination stops.

What the pairing actually is

CJC-1295 is a tetra-substituted analogue of hGRF(1-29)NH2, the biologically active fragment of human growth-hormone-releasing hormone. Two forms circulate under the same name and they are not interchangeable. The with DAC form carries a C-terminal N-epsilon-maleimidopropionamide-lysine group - a Drug Affinity Complex - that bonds covalently to serum albumin and stretches the effective half-life into days. The no-DAC form, usually called Mod GRF 1-29, omits that group and has a half-life of roughly thirty minutes. A protocol that does not say which form it used has not said very much.

Ipamorelin is the pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2, a selective agonist at the ghrelin receptor GHS-R1a.

Neither peptide is approved for human use in any jurisdiction; both are supplied as research chemicals. Their compounding status has moved twice in recent years: both were added to the FDA's interim Section 503A Category 2 bulk-substances list in September 2023, citing immunogenicity, peptide-impurity and limited-safety concerns, with CJC-1295 additionally flagged for cardiac effects, then removed from Category 2 in September 2024 after the nominators withdrew, with Pharmacy Compounding Advisory Committee re-evaluation scheduled for late 2024. Both are prohibited in sport at all times under WADA Section S2, and potentially under S0 as non-approved substances.

Why two receptors, and what happens at each

CJC-1295 binds the growth-hormone-releasing-hormone receptor, a class-B G-protein-coupled receptor on pituitary somatotrophs, raising cyclic AMP through Gs and driving both synthesis and release of growth hormone. Ipamorelin binds GHS-R1a on the same cells and raises intracellular calcium through Gq. Two receptors, two second messengers, one output.

The mechanistic case for combining them is that the pathways are independent and therefore additive - or better than additive. There is direct cell-level evidence for the stronger claim: co-activating the cloned growth-hormone-secretagogue receptor and the GHRH receptor in transfected HeLa cells produced a cyclic AMP response approximately twice that of GHRH-receptor activation alone, which points to direct receptor cross-talk rather than simple summation ^[12].

There is a second argument that is often skipped in summaries of this pairing. Ghrelin-receptor agonism acts on hypothalamic somatostatin tone, and somatostatin is the brake on growth-hormone release. Easing the brake while pressing the accelerator is a different maneuver from pressing the accelerator twice, and it is part of why the co-stimulation literature reports supra-additive pulses. Neither argument has yet been converted into a controlled human endpoint.

What the studies measured, and what was never studied

CJC-1295, single dose, healthy adults. A single subcutaneous dose of CJC-1295 with DAC raised mean plasma growth hormone two- to ten-fold for six days or more, and IGF-1 1.5- to three-fold for nine to eleven days, in healthy adults. After multiple doses, IGF-1 remained above baseline for as long as 28 days ^[10]. That is the most consequential number on this page, because it establishes that the CJC-1295 half is not a pulse agent at all but a multi-day exposure.

The albumin mechanism, measured. The maleimidopropionamide-lysine group binds covalently to the Cys34 thiol of serum albumin. In rats, that bioconjugation produced roughly a four-fold increase in growth-hormone area-under-the-curve over two hours compared with unmodified hGRF(1-29), with albumin-bound peptide still detectable in plasma beyond 72 hours ^[11]. The engineering works exactly as designed; the question is whether a multi-day GHRH-pathway drive is the same intervention as the pulsatile one the synergy literature studied.

The class safety review. A review of growth-hormone secretagogues found them well tolerated overall, with the chief safety concern being increased blood glucose arising from decreased insulin sensitivity, and concluded that long-term data on cancer incidence and mortality are still needed ^[9].

What a properly trialed GHRH analogue looks like. A 2026 meta-analysis of five randomized controlled trials of the GHRH analogue tesamorelin found significant reductions in visceral adipose tissue (mean difference -27.71 cm2) and hepatic fat (mean difference -4.28%), increased lean body mass (mean difference +1.42 kg) and increased IGF-1, with no serious adverse events and no glucose perturbation ^[8]. That result belongs to tesamorelin, not to CJC-1295, and it is included here for exactly that reason: it shows what a GHRH-analogue evidence base looks like once the trials are actually run.

What was never studied. No controlled clinical trial has evaluated CJC-1295 and ipamorelin as a fixed combination for any outcome. There is no published human pharmacokinetic profile for the pair, no dose-ranging study, and no head-to-head comparison against sermorelin, tesamorelin or recombinant growth hormone. The synergy literature cited in support of the pairing used related peptides in cells and animals, not this combination in people, and the most-cited animal result for the pair - improved maximum tetanic tension in a murine glucocorticoid-induced muscle-loss model - comes with its reviewers' own conclusion that the evidence remains limited to animal studies ^[7].

Reported effects, cautions and safety

The first part of this section is anecdotal, not clinical evidence. It summarizes community self-report from people using the pairing outside any study, with dose, source, purity and concurrent diet and training all unverified. No doses appear here, because none of these accounts carry a verified one.

Deeper and more restorative sleep is by a clear margin the most-cited reported benefit, usually described as appearing within the first week or two. Faster recovery between training sessions and reduced next-day soreness are also frequently reported. Reported less often: a gradual shift toward leaner body composition from roughly week five onward, subjective improvement in skin, nails, hair and joint comfort over a couple of months, and better daytime energy and mood - which the people reporting it usually frame as downstream of better sleep rather than direct. Increased appetite in the hours after dosing is frequently reported, which is unsurprising given the ghrelin-receptor half of the pairing.

Reported adverse effects run to injection-site redness, itching or swelling, the most consistently mentioned of all; transient puffiness or water retention in the first two to four weeks; a warm facial flush shortly after injection; tingling, numbness or carpal-tunnel-like hand symptoms; grogginess or a spacey feeling after dosing; and brief light-headedness. Again, uncontrolled self-report rather than measured outcomes.

Cautions grounded in mechanism and literature. The pairing is designed to raise growth hormone and therefore IGF-1, and IGF-1 is a mitogen, so active or recent malignancy is the first mechanistic contraindication. That is class-level reasoning rather than an observed event: no carcinogenicity or tumor-promotion study of the blend exists, and no such signal has been observed because no such study has been run.

Reduced insulin sensitivity with raised blood glucose is the class's most consistent metabolic effect ^[9], and it is least predictable in anyone whose glucose handling is already impaired.

Fluid retention, carpal-tunnel-type nerve compression and joint pain are the classic consequences of growth-hormone excess, and a protocol built to raise growth-hormone output inherits them as mechanistically expected nuisances rather than as observed harms from any blend trial.

The mismatch between the halves deserves its own caution. Pairing a multi-day albumin-bound agent ^[10][11] with a compound cleared within hours means the intended pulsatile synergy and the net growth-hormone exposure are uncharacterized for any specific protocol, and continuous GHRH-pathway drive from the DAC form is a distinctly different exposure profile from the short pulses the synergy literature studied.

The plain gaps stand: no approval, no long-term human safety database for either component or the pair, no pharmaceutical quality assurance on research-grade material, and no published safety or pharmacokinetic characterization of the subcutaneous self-administration route that dominates community use.

Where it sits on the growth-hormone axis

The pairing is the most-discussed protocol on this axis and the least evidenced. High visibility with low proof is exactly the pattern an applied reading of this literature exists to make legible.

It is worth being fair to the underlying pharmacology. The two-receptor argument is real, it has cell-level support ^[12], and the individual components have been measured carefully - the CJC-1295 half in healthy adults ^[10] and in rats ^[11], the ipamorelin half in its founding characterization ^[6] and in a human pharmacokinetic study ^[4]. Nothing about the design is implausible.

What is missing is the step that converts pharmacology into evidence: a study with a defined population, a stated duration, a pre-specified endpoint and a control arm. Tesamorelin, on the next page, is what that step looks like when it is taken. The distance between these two pages is the entire subject of this site.